Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoldonrasib with or without daraxonrasib plus pembrolizumab with or without chemotherapy in RAS G12D-mutant NSCLC
NL-OMON59320Phase 2Recruiting
- Sponsor
- Revolution Medicines
- Start
- Nov 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of zoldonrasib, daraxonrasib, pembrolizumab and pemetrexed in non-small cell lung cancer (NSCLC) (4 arms), sponsored by Revolution Medicines. Primary endpoints: Incidence of dose-limiting toxicities and Incidence of adverse events and clinically significant safety changes. Started Nov 2025; status: recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON59320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59320.